Clinical Trials
99 trialsNRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
St. Jude Children's Research Hospital
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Beijing Tongren Hospital
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
Washington University School of Medicine
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
PETHEMA Foundation
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
The Children's Hospital of Zhejiang University School of Medicine
Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial
Mayo Clinic
SELVEDge
University of Miami
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
Sun Yat-sen University
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Hackensack Meridian Health
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
University of California, Davis
A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes
University Health Network, Toronto
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma
Mayo Clinic
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Dana-Farber Cancer Institute
SINE
University of Chicago
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute
A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies
National University Hospital, Singapore
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Duke University
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
The First Affiliated Hospital with Nanjing Medical University
Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation
Chinese PLA General Hospital
Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)
National University Hospital, Singapore
SeliSarc
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
Second Affiliated Hospital of Soochow University
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients
Institute of Hematology & Blood Diseases Hospital, China
SABLe
Odense University Hospital
Second-line Immunotherapy for ES-SCLC
Tianjin Medical University Cancer Institute and Hospital
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
University of Rochester
Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT
Ruijin Hospital
A Multicenter Study on the Treatment of MDS/MPN Overlap Syndrome With AZA or Rux Combined With Selinexor
Peking Union Medical College Hospital
Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies
Vanderbilt-Ingram Cancer Center
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Academic and Community Cancer Research United
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL
Ruijin Hospital
Selinexor, Anti-PD-1 Antibody and P-GemOx Regimen in R/R NKTCL
Ruijin Hospital
Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant
Washington University School of Medicine
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Sun Yat-sen University
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
University of Texas Southwestern Medical Center
Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors
St. Jude Children's Research Hospital
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Loyola University